Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Calliditas Therapeutics (CALT – Research Report) today and set a price target of $55.00. The company’s shares closed yesterday at $19.45.
According to TipRanks, Samimy is a 4-star analyst with an average return of 9.0% and a 45.94% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, RegenXBio, and Jazz Pharmaceuticals.
Currently, the analyst consensus on Calliditas Therapeutics is a Strong Buy with an average price target of $40.93, an 110.44% upside from current levels. In a report released on April 11, H.C. Wainwright also maintained a Buy rating on the stock with a $50.00 price target.
The company has a one-year high of $29.30 and a one-year low of $15.25. Currently, Calliditas Therapeutics has an average volume of 7,387.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Calliditas Therapeutics (CALT) Company Description:
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
Read More on CALT:
